Marian Schini
@marianschini.bsky.social
Consultant in Metabolic Bone. Sheffield Teaching Hospitals. University of Sheffield,UK. Mellanby centre for musculoskeletal research. Background in endocrinology. MD, PhD, she/her.
Reposted by Marian Schini
Exciting news!
ASBMR's investment and hard work has resulted in the FDA approving the use of bone mineral density as a surrogate biomarker for fracture reduction in clinical trials of osteoporosis treatments.
ASBMR's investment and hard work has resulted in the FDA approving the use of bone mineral density as a surrogate biomarker for fracture reduction in clinical trials of osteoporosis treatments.
December 19, 2025 at 9:32 PM
Exciting news!
ASBMR's investment and hard work has resulted in the FDA approving the use of bone mineral density as a surrogate biomarker for fracture reduction in clinical trials of osteoporosis treatments.
ASBMR's investment and hard work has resulted in the FDA approving the use of bone mineral density as a surrogate biomarker for fracture reduction in clinical trials of osteoporosis treatments.